Effector Therapeutics Inc (EFTR) Return on Equity ROE from the first quarter 2024 to first quarter 2023 and annually, average high and low, overall ranking from Mar 31 2024 to Mar 31 2023 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Effector Therapeutics Inc   (NASDAQ: EFTR)

Effector Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Effector Therapeutics Inc in the first quarter 2024?
Due to the lack of equity, it was not possible to calculate Effector Therapeutics Inc 's return on equity (ROE) in its first quarter 2024

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter
Y / Y Equity Change - - - -86.88 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -35 -36 -36 -37 -36
Return On Equity (TTM) - - - -1125.65 % -472.45 %
EFTR's Total Ranking # # # # #
Equity (TTM) in Millions 1 -6 -4 3 -5
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to EFTR Management Effectiveness >> EFTR's 5 Years Annual ROE >> Compare EFTR ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





EFTR Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021

Total Equity in Millions -6 4 17 0 0
Y / Y Equity Change - -77.46 % - - -
Net Income in Millions -36 -23 16 0 0
Y / Y Net Income Change - - - - -
Return On Equity - -581.75 % 91.4 % - -

Back to EFTR Management Effectiveness >> EFTR's 5 Years Annual ROE >> Compare EFTR ROE to its Competitors




Annual Roe Comment
Despite deterioration in net income, company improved ROE to in 2023, company improved ROE to 91.4 % compared to the prior year.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
EFTR's' Return on Equity at Yahoo Finance
EFTR's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for EFTR's Competitors
Subscribers only: Roe for Effector Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for EFTR's Customers




Companies with similar Return On Equity at Mar 31 2024, within Healthcare Sector ROE
Hca Healthcare Inc   806.86 %
Biomx Inc  595.88 %
Cardiff Lexington Corporation  552.36 %
Ir med Inc   481.97 %

Date modified: 2026-09-26T07:39:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.